In CLL, CD40 is frequently over-activated in response to immunomodulatory effects, demonstrating that the tumor microenvironment can play a significant role in VEN response and resistance and offers possibilities for therapeutic intervention [30, 32, 33]. This evidence concerns the gene CD40 and B-cell chronic lymphocytic leukemia.